[Value of BCL-2 and PD-L1 Combined Detection in Predicting the Prognosis of Primary Acute Leukemia].

Objective: To evaluate the clinical value of combined detection of BCL-2 and PD-L1 in predicting the prognosis of newly diagnosed patients with acute leukemia (AL).
Methods: A total of 100 cases of AL in our hospital from Jan. 2013 to Sep. 2016 were enrolled in the study. The mRNA expression of BCL-2 and PD-L1 in peripheral blood of patients was detected by RT-PCR, and the prognosis of the patients was followed up. According to the follow-up results, these patients were divided into complete remission group and no remission group, the statistical analysis of different indexes predicting the prognosis was performed.
Results: Compared with the healthy control group, the positive rates of BCL-2 and PD-L1 in the bone marrow specimens of AL patients significantly increased (P<0.01). The BCL-2 predicting the prognosis of patients showed that the area under the curve (AUC) was 0.725(P=0.006), the diagnostic threshold was 1.550, the sensitivity(Sen) and specificity(Spe) were 72% and 84%, respectively. The single PD-L1 detection for predicting the prognosis of patients showed that AUC was 0.740 (P=0.004), diagnostic threshold was 12.500, Sen and Spe were 66.7% and 73.1%, respectively. The diagnostic index of combined detection was 77.90, which were higher than that of series detection 54.75, and higher than that of the independent diagnostic index.
Conclusion: Detection of BCL-2 combined with PD-L1 can be used to evaluate the prognosis of patients with newly diagnosed acute leukemia, which can improve the specificity and sensitivity of the detection, and has higher clinical diagnostic value than single actection.